$3500 | Single User
$7000 | Site License
$10500 | Enterprise License

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H1 2017 [Report Updated: 20-06-2017]

Published by Global Markets Direct: 20 Jun 2017 | 87134 | In Stock

Introduction

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H1 2017

Summary

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Galectin-3 is a protein encoded by the LGALS3 gene. It mediates with the alpha-3, beta-1 integrin the stimulation by CSPG4 of endothelial cells migration. It acts as a pre-mRNA splicing factor. It is involved in acute inflammatory responses including neutrophil activation and adhesion, chemoattraction of monocytes macrophages, opsonization of apoptotic neutrophils, and activation of mast cells.

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) pipeline Target constitutes close to 18 molecules. Out of which approximately 18 molecules are developed by Companies.The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 12 and 4 respectively. Report covers products from therapy areas Oncology, Cardiovascular, Gastrointestinal, Genito Urinary System And Sex Hormones, Respiratory, Dermatology, Musculoskeletal Disorders, Ophthalmology, Undisclosed, Immunology and Metabolic Disorders which include indications Kidney Fibrosis, Liver Fibrosis, Myocardial Fibrosis, Atopic Dermatitis, Fibrosis, Liver Cirrhosis, Non-Alcoholic Steatohepatitis (NASH), Portal Hypertension, Prostate Cancer, Pulmonary Arterial Hypertension, Pulmonary Fibrosis, Unspecified, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colorectal Cancer, Corneal Neovascularization, Diabetic Nephropathy, Head And Neck Cancer Squamous Cell Carcinoma, Idiopathic Pulmonary Fibrosis, Keratoconjunctivitis sicca (Dry Eye), Metastatic Breast Cancer, Metastatic Melanoma, Multiple Myeloma (Kahler Disease), Non-Small Cell Lung Cancer, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris) and Sarcomas.

The latest report Galectin 3 - Pipeline Review, H1 2017, outlays comprehensive information on the Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3)

- The report reviews Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics and enlists all their major and minor projects

- The report assesses Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H1 2017 [Report Updated: 20-06-2017]

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Overview

    Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Therapeutics Development

    Products under Development by Stage of Development

    Products under Development by Therapy Area

    Products under Development by Indication

    Products under Development by Companies

    Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Therapeutics Assessment

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Companies Involved in Therapeutics Development

    Angion Biomedica Corp

    Bristol-Myers Squibb Company

    Galectin Therapeutics Inc

    GlycoMimetics Inc

    iTeos Therapeutics SA

    MandalMed Inc

    Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Drug Profiles

    ANG-4021 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Aptamers to Inhibit Galectin-3 for Atopic Dermatitis - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    G-XXX - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Gal-200 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    GAL-300 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Gal-400 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    GMCT-01 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    GRMD-02 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    GRMD-03 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    GRMD-04 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    KTI - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Monoclonal Antibody to Inhibit Galectin-3 for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Protearin - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule to Inhibit Galectin-1, 3, 9 for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule to Inhibit Galectin-3 for Fibrosis, Oncology and Cardiovascular Disease - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    TD-139 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    TFD-100 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Dormant Products

    Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Discontinued Products

    Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Product Development Milestones

    Featured News & Press Releases

    Jun 13, 2017: Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial

    Jun 06, 2017: Autoimmune Disease Patent Granted to Galectin Therapeutics

    Apr 25, 2017: Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02

    Apr 18, 2017: Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress 2017

    Mar 14, 2017: GR-MD-02 Demonstrates Clinically Significant Effect in Patients with Severe and Refractory Atopic Dermatitis (Eczema)

    Mar 06, 2017: Galectin’s GR-MD-02 Demonstrates Efficacy in Patients with Moderate to Severe Plaque Psoriasis

    Feb 07, 2017: Combination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Phase 1 Clinical Trials

    Feb 01, 2017: Galectin Therapeutics Announces Achievement of Key Milestones Related to NASH-CX Clinical Trial

    Nov 21, 2016: Galectin Therapeutics and CTI Announce Positive New Psoriasis and Atopic Dermatitis Clinical Data

    Nov 10, 2016: Galectin Therapeutics Announces Positive New Psoriasis and Atopic Dermatitis Clinical Data, Seeking Strategic Partnerships for Therapy of Severe Skin Diseases

    Oct 07, 2016: Galectin Therapeutics to Present Clinical Data on Selective Non-Invasive Tests for the Development of Novel Therapies for Nonalcoholic Steatohepatitis

    Sep 27, 2016: Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis

    Aug 25, 2016: Galectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial

    Aug 02, 2016: Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis

    Jul 12, 2016: Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

87134 | GMDHC0872TDB

Number of Pages

77

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Galectin Therapeutics Inc (GALT) - Financial and Strategic SWOT Analysis Review
SummaryGalectin Therapeutics Inc (Galectin Therapeutics), formerly Pro-Pharmaceuticals, Inc. is a bi...
13 Jan 2017 by Global Data USD $300 More Info
Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) - Pipeline Review, H2 2016
Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 ...
28 Dec 2016 by Global Markets Direct USD $3,500 More Info
Galectin Therapeutics Inc (GALT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGalectin Therapeutics Inc (Galectin Therapeutics), formerly Pro-Pharmaceuticals, Inc. is a bi...
28 Nov 2016 by Global Data USD $250 More Info
Galectin Therapeutics, Inc. (GALT) - Financial and Strategic SWOT Analysis Review
SummaryGalectin Therapeutics, Inc. (Galectin Therapeutics) is a biotechnology company that offers th...
11 Jul 2016 by Global Data USD $300 More Info
Galectin Therapeutics, Inc. (GALT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGalectin Therapeutics, Inc. (Galectin Therapeutics) is a biotechnology company that offers th...
06 May 2016 by Global Data USD $250 More Info
Galectin Therapeutics, Inc. (GALT) - Financial and Strategic SWOT Analysis Review
SummaryGalectin Therapeutics, Inc. (Galectin Therapeutics) is a biotechnology company that offers th...
15 Apr 2016 by Global Data USD $300 More Info
Galectin Therapeutics, Inc. (GALT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGalectin Therapeutics, Inc. (Galectin Therapeutics) is a biotechnology company that offers th...
10 Mar 2016 by Global Data USD $250 More Info
Galectin Therapeutics, Inc. (formerly Pro-Pharmaceuticals, Inc.) – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Project Synopsis:Datamonitor's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and In...
10 Mar 2016 by Marketline USD $350 More Info
Galectin Therapeutics, Inc. (GALT) - Financial and Strategic SWOT Analysis Review
SummaryGalectin Therapeutics, Inc. (Galectin Therapeutics) is a biotechnology company that offers th...
09 Jan 2016 by Global Data USD $300 More Info
Galectin Therapeutics, Inc. (GALT) - Financial and Strategic SWOT Analysis Review
SummaryGalectin Therapeutics, Inc. (Galectin Therapeutics) is a biotechnology company that offers th...
08 Nov 2015 by Global Data USD $300 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H1 2017 [Report Updated: 20-06-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data